Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.
Novavax Inc. develops and partners vaccine technologies built around Matrix-M adjuvant technology and protein-based nanoparticles. Company news centers on marketed vaccine products, including Nuvaxovid and R21/Matrix-M, licensing and material-transfer agreements with pharmaceutical companies, and research programs for infectious disease and other vaccine applications.
Recurring updates also cover quarterly financial results, revenue from product sales and partner arrangements, R&D prioritization such as its C. difficile vaccine candidate, operating-efficiency initiatives, investor conference participation, and leadership changes within research and development.
Novavax (Nasdaq: NVAX) will participate in the BofA Securities 2026 Health Care Conference with a fireside chat on Wednesday, May 13, 2026 at 3:00–3:30 p.m. PT in Las Vegas. A webcast will be available on the company website and a replay will be accessible for 30 days.
Novavax (Nasdaq: NVAX) reported $140 million total revenue for Q1 2026, down 79% year-over-year from $667 million. Licensing, royalties and other revenue totaled $97 million, including a $30 million upfront payment from Pfizer. Net loss was $9 million.
Cash totaled $795 million and Novavax closed a $330 million credit facility. The company reiterated 2026 guidance: Adjusted total revenue $230–$270M and Non-GAAP combined R&D and SG&A $310–$340M.
Novavax (Nasdaq: NVAX) will report first quarter 2026 financial results and operational highlights on May 6, 2026 at 8:30 a.m. ET. A live webcast and conference call will be available, with replay access from 11:30 a.m. ET May 6 through 11:59 p.m. ET May 13, 2026.
Participants may register for automated call-back or dial in directly; the webcast will remain on the investor site through June 6, 2026.
Novavax (NASDAQ: NVAX) appointed Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development effective March 30, 2026. Dr. Walker, a pulmonologist with more than 30 years in drug and vaccine development, previously served as Novavax Chief Medical Officer and will report to CEO John C. Jacobs. He will oversee preclinical and clinical R&D, emphasize data generation to support partnering, and advance Matrix adjuvant innovation and the company pipeline. Dr. Ruxandra Draghia-Akli has departed to pursue other opportunities.
Novavax (Nasdaq: NVAX) will participate in three investor events in March 2026: TD Cowen Health Care Conference (fireside chat, March 3, Boston), Leerink Partners Global Healthcare Conference (fireside chat, March 10, Miami Beach), and Jefferies Biotech on the Beach (investor meetings, March 11, Miami Beach).
A live webcast of the fireside chats will be available at the company’s Events and Presentations page, with replays accessible for 30 days.
Novavax (NASDAQ: NVAX) reported Q4 2025 revenue of $147M and full‑year 2025 revenue of $1.123B. The company earned $225M in Sanofi milestones in 2025 and received a $30M upfront payment from Pfizer in Jan 2026 for a Matrix‑M license. Year‑end cash was $751M and Novavax announced a $330M credit facility in Feb 2026. Management targets reduced combined R&D and SG&A non‑GAAP expense of $310–$340M for 2026 and expects adjusted total revenue of $230–$270M for 2026.
Novavax (Nasdaq: NVAX) will report fourth quarter and full year 2025 financial results and operational highlights on February 26, 2026 at 8:30 a.m. ET.
Investors may join the live conference call by registering for an automated call back or by dialing in; a replay and webcast will be available after the event.
Novavax (NASDAQ: NVAX) announced a non-exclusive license agreement with Pfizer dated January 20, 2026 for use of Novavax's Matrix-M® adjuvant in up to two disease areas. Novavax will receive a $30 million upfront payment and is eligible for up to $500 million in development and sales milestones plus tiered high mid-single digit percent royalties on sales of Pfizer products containing Matrix-M. Pfizer will be solely responsible for development and commercialization of its Matrix-M–containing products, while Novavax will supply Matrix-M for Pfizer's programs.
Novavax (Nasdaq: NVAX) will participate in the 44th Annual J.P. Morgan Healthcare Conference.
The company will present on Wednesday, January 14, 2026 at 4:30 p.m. Pacific Time in San Francisco, CA. A live webcast will be available on the company's Events & Presentations page at ir.novavax.com, and a replay will be available for 30 days following the presentation.
Novavax (Nasdaq: NVAX) will participate in the Jefferies London Healthcare Conference with a fireside chat on Wednesday, November 19, 2025 at 4:30 p.m. GMT in London, United Kingdom.
A webcast of the fireside chat will be available on the company’s Events & Presentations page at ir.novavax.com, and a replay will be accessible for 30 days.